Alnylam Pharmaceuticals (ALNY) Q3 2025 10-Q Quarterly Report
Alnylam Pharmaceuticals (ALNY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Alnylam Pharmaceuticals Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No quarterly revenue or YoY figures disclosed in this MD&A excerpt
- • No profitability or margin data provided for current quarter or YoY comparison
- • No segment or product line performance data included
- • Cash, equivalents, marketable securities, and Revolving Credit Agreement availability deemed sufficient for next 12 months as of Sept 30, 2025
- • Management warns potential need for significant additional funds earlier due to development and commercialization risks
Risk Factors
- • New risk: AMVUTTRA U.S. launch March 2025 for ATTR amyloidosis with cardiomyopathy increases commercialization risk
- • Updated financial risk: Accumulated deficit $7.16B as of Sept 30, 2025; product revenues $851.1M Q3, $1.99B YTD with ongoing operating losses
- • Regulatory risk: Ongoing regulatory oversight plus potential liability from unapproved product promotion or off-label marketing
- • Operational risk: Dependence on collaborators Roche, Regeneron, Novartis, Sanofi for development, commercialization, and sales execution
- • Financial risk: $2.72B cash and equivalents exposed to credit, liquidity, market risks; significant foreign currency exposure especially JPY, EUR, GBP impacting revenues and expenses
Alnylam Pharmaceuticals Q3 2025 Quarterly FinancialsXBRL
Revenue
$1.2B
▲ +149.3% YoY▲ +61.4% QoQ
Net Income
$251M
▲ +325.0% YoY▲ +478.8% QoQ
Net Margin
20.1%
▲ +4238bp YoY▲ +2867bp QoQ
Source: XBRL data from Alnylam Pharmaceuticals Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Alnylam Pharmaceuticals Quarterly Reports
Get deeper insights on Alnylam Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.